18350617. SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 simplified abstract (Fred Hutchinson Cancer Center)
Contents
- 1 SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1
Organization Name
Inventor(s)
Jason Price of Seattle WA (US)
Colin E. Correnti of Seattle WA (US)
James M. Olson of Seattle WA (US)
SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 - A simplified explanation of the abstract
This abstract first appeared for US patent application 18350617 titled 'SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1
Simplified Explanation
The abstract describes single-domain antibodies that bind receptor tyrosine kinase (ROR1) for various applications such as research, imaging, diagnosis, and treatment of ROR1-related conditions. These antibodies can be used as anti-cancer therapeutics, imaging/diagnostic agents, or recombinant receptors.
- Single-domain antibodies bind receptor tyrosine kinase (ROR1).
- Can be used in research, imaging, diagnosis, and treatment of ROR1-related conditions.
- Potential applications in anti-cancer therapeutics, imaging/diagnostics, and recombinant receptors.
Potential Applications
The technology can be applied in various fields such as cancer therapy, diagnostic imaging, and research on ROR1-related conditions.
Problems Solved
The technology addresses the need for targeted therapies and diagnostic tools for ROR1-related conditions, particularly in cancer treatment and imaging.
Benefits
The use of single-domain antibodies provides a more targeted and efficient approach to treating ROR1-related conditions, potentially leading to improved outcomes for patients.
Potential Commercial Applications
The technology has potential commercial applications in the development of anti-cancer therapeutics, diagnostic imaging agents, and research tools for ROR1-related conditions.
Possible Prior Art
Prior art may include existing antibodies or targeting molecules for ROR1, as well as previous research on ROR1-related conditions and therapies.
Unanswered Questions
How do these single-domain antibodies compare to traditional antibodies in terms of efficacy and specificity for ROR1 targeting?
The article does not provide a direct comparison between single-domain antibodies and traditional antibodies in terms of efficacy and specificity for targeting ROR1. Further studies or data may be needed to address this question.
What are the potential challenges or limitations in using single-domain antibodies for ROR1 targeting in clinical applications?
The article does not discuss potential challenges or limitations in using single-domain antibodies for ROR1 targeting in clinical applications. Additional research or clinical trials may be necessary to evaluate the feasibility and effectiveness of this approach.
Original Abstract Submitted
Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.
